Login Register Cart 0
Generic placeholder image

Recent Advances in Inflammation & Allergy Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-2708
ISSN (Online): 2772-2716

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Narrative Review of Anti-CD3 Antibody and Anti-CD20 Antibody: Immunotherapeutic Strategies to Treat and Prevent Type 1 Diabetes

Author(s): Prajakta Kashalikar, Shivani Desai*, Avinash Sanap, Madhura Shekatkar and Ramesh Bhonde

Volume 17, Issue 1, 2023

Published on: 13 December, 2022

Page: [64 - 70] Pages: 7

DOI: 10.2174/2772270817666221122103029

Price: $65

Abstract

Background and Objective: Type 1 diabetes mellitus is a complex disease defined by the loss of pancreatic cells, which leads to complete insulin insufficiency. The Diabetes Control and Problems Trial defines the aims of Type 1 diabetes therapy as achieving adequate glycaemic control, and preventing and avoiding recurrent bouts of hypoglycaemia. Despite ongoing efforts to improve insulin therapy regimens, the actual hormone substitute therapy treats just the symptoms of the disease, with no influence on disease pathology or etiopathogenesis. In recent decades, there has been a lot of interest in preventative techniques in high-risk patients, based on the theory that if a therapeutic intervention is adopted early in the disease, it can help maintain endogenous cell function by protecting the remaining cell reservoir from autoimmune attack.

Methods: Based on preclinical and clinical data, we have discussed some immunotherapeutic in this meta-analysis. We referred to the preclinical and clinical studies for teplizumab and rituximab from authentic databases and compiled the data. We used statistical analysis to do a meta-analysis.

Results: In two immunotherapeutic anti-CD3 antibodies and anti-CD20 antibodies examples, teplizumab and rituximab, respectively, shows better efficacy as well as fewer side effects. We have discussed this drug briefly based on their mechanism of action and meta-analysis, which compare clinical efficacy.

Conclusion: Immunotherapeutic can be a better option for preventing and protecting type one diabetes. Since, the existing literature does not have enough data to support any single drug concluding the same will not be appropriate. Hence further studies are required wherein different drugs can be compared with similar sample sizes for each group of drugs.

Keywords: Type 1 diabetes, immunotherapy, meta-analysis, rituximab, teplizumab, anti-CD3.

« Previous Next »
Graphical Abstract

[1]
Smith EL, Peakman M. Peptide immunotherapy for type 1 diabetes-clinical advances. Front Immunol 2018; 9(FEB): 392.
[http://dx.doi.org/10.3389/fimmu.2018.00392] [PMID: 29541078]
[2]
DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet 2018; 391(10138): 2449-62.
[http://dx.doi.org/10.1016/S0140-6736(18)31320-5] [PMID: 29916386]
[3]
Rapini N, Schiaffini R. Immunotherapy strategies for the prevention and treatment of distinct stages of type 1 diabetes: An overview. Int J Mol Sci 2020; 1-11.
[4]
Perri V, Russo B, Crinò A, et al. Expression of PD-1 molecule on regulatory T lymphocytes in patients with insulin-dependent diabetes mellitus. Int J Mol Sci 2015; 16(9): 22584-605.
[http://dx.doi.org/10.3390/ijms160922584] [PMID: 26393578]
[5]
Pellegrino M, Crinò A, Rosado MM, Fierabracci A. Identification and functional characterization of CD8+ T regulatory cells in type 1 diabetes patients. PLoS One 2019; 14(1): e0210839.
[http://dx.doi.org/10.1371/journal.pone.0210839] [PMID: 30650147]
[6]
Di Lorenzo TP, Peakman M, Roep BO. Translational mini-review series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes. Clin Exp Immunol 2007; 148(1): 1-16.
[http://dx.doi.org/10.1111/j.1365-2249.2006.03244.x] [PMID: 17349009]
[7]
Care D, Suppl SS. American Diabetes Association 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021. Diabetes Care 2021; 44 (Suppl. 1): S15-33.
[PMID: 33298413]
[8]
Von A. Bench to Clinic Symposia Immunotherapy for the Prevention and Treatment of Type 1 Diabetes Optimizing the path from bench to bedside. 2009.
[9]
Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the endocrine society, and the american diabetes association. Diabetes Care 2015; 38(10): 1964-74.
[http://dx.doi.org/10.2337/dc15-1419] [PMID: 26404926]
[10]
Ni Q, Pham NB, Meng WS, Zhu G, Chen X. Advances in immunotherapy of type I diabetes. Adv Drug Deliv Rev 2019; 139: 83-91.
[http://dx.doi.org/10.1016/j.addr.2018.12.003] [PMID: 30528629]
[11]
Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The diabetes prevention trial--type 1. Diabetes Care 2005; 28(5): 1068-76.
[http://dx.doi.org/10.2337/diacare.28.5.1068] [PMID: 15855569]
[12]
England TN. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002; 346(22): 1685-91.
[http://dx.doi.org/10.1056/NEJMoa012350] [PMID: 12037147]
[13]
Brophy S, Yderstræde K, Mauricio D, et al. Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults. Diabetes Care 2008; 31(3): 439-41.
[http://dx.doi.org/10.2337/dc07-1308] [PMID: 18083788]
[14]
Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998; 47(6): 894-9.
[http://dx.doi.org/10.2337/diabetes.47.6.894] [PMID: 9604865]
[15]
Hinke SA. Diamyd, an alum-formulated recombinant human GAD65 for the prevention of autoimmune diabetes. Curr Opin Mol Ther 2008; 10(5): 516-25.
[PMID: 18830927]
[16]
Elding Larsson H, Lundgren M, Jonsdottir B, Cuthbertson D, Krischer J. Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial. Pediatr Diabetes 2018; 19(3): 410-9.
[http://dx.doi.org/10.1111/pedi.12611] [PMID: 29171140]
[17]
Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994; 91(1): 123-7.
[http://dx.doi.org/10.1073/pnas.91.1.123] [PMID: 8278351]
[18]
Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54(6): 1763-9.
[http://dx.doi.org/10.2337/diabetes.54.6.1763] [PMID: 15919798]
[19]
von Herrath MG, Coon B, Wolfe T, Chatenoud L. Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. J Immunol 2002; 168(2): 933-41.
[http://dx.doi.org/10.4049/jimmunol.168.2.933] [PMID: 11777992]
[20]
Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352(25): 2598-608.
[http://dx.doi.org/10.1056/NEJMoa043980] [PMID: 15972866]
[21]
Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 2019; 381(7): 603-13.
[http://dx.doi.org/10.1056/NEJMoa1902226] [PMID: 31180194]
[22]
Aronson R, Gottlieb PA, Christiansen JS, et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 2014; 37(10): 2746-54.
[http://dx.doi.org/10.2337/dc13-0327] [PMID: 25011949]
[23]
Hu C, Rodriguez-Pinto D, Du W, et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007; 117(12): 3857-67.
[http://dx.doi.org/10.1172/JCI32405] [PMID: 18060033]
[24]
Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, Mcgee PF. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361(22): 2143-52.
[25]
Mandrup-Poulsen T, Zumsteg U, Reimers J, et al. Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic β-cell destruction in insulin-dependent diabetes mellitus. Cytokine 1993; 5(3): 185-91.
[http://dx.doi.org/10.1016/1043-4666(93)90003-N] [PMID: 8218929]
[26]
Argilés JM, López-Soriano J, López-Soriano FJ. Cytokines and diabetes: The final step? Involvement of TNF-alpha in both type I and II diabetes mellitus. Horm Metab Res 1994; 26(10): 447-9.
[http://dx.doi.org/10.1055/s-2007-1001730]
[27]
Held W, MacDonald HR, Weissman IL, Hess MW, Mueller C. Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes. Proc Natl Acad Sci USA 1990; 87(6): 2239-43.
[http://dx.doi.org/10.1073/pnas.87.6.2239] [PMID: 2179951]
[28]
Campbell IL, Iscaro A, Harrison LC. IFN-gamma and tumor necrosis factor-alpha. Cytotoxicity to murine islets of Langerhans. J Immunol 1988; 141(7): 2325-9.
[PMID: 3139756]
[29]
Mandrup-Poulsen T, Bendtzen K, Dinarello CA, Nerup J. Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity. J Immunol 1987; 139(12): 4077-82.
[PMID: 3320203]
[30]
Ye Q, Lin YN, Xie MS, et al. Effects of etanercept on the apoptosis of ganglion cells and expression of Fas, TNF-α caspase-8 in the retina of diabetic rats. Int J Ophthalmol 2019; 12(7): 1083-8.
[http://dx.doi.org/10.18240/ijo.2019.07.05] [PMID: 31341796]
[31]
Mastrandrea L, Yu J, Behrens T, et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009; 32(7): 1244-9.
[http://dx.doi.org/10.2337/dc09-0054] [PMID: 19366957]
[32]
Hsu C, Li Y, Hsu C, Cheng J, Lin M, Cheng K. Etanercept ameliorates cardiac fibrosis in rats with diet-induced obesity. Pharmaceuticals 2021; 14(4): 320.
[http://dx.doi.org/10.3390/ph14040320]
[33]
Harada M, Kishimoto Y, Makino S. Prevention of overt diabetes and insulitis in NOD mice by a single BCG vaccination. Diabetes Res Clin Pract 1990; 8(2): 85-9.
[http://dx.doi.org/10.1016/0168-8227(90)90017-N] [PMID: 2307094]
[34]
1142-P: Update on BCG Clinical Trial Programs in Patients with Advanced Type 1 Diabetes. Diabetes 2021; 70(S1): 1142.
[35]
Moin ASM, Nandakumar M, Diane A, Dehbi M, Butler AE. The role of heat shock Proteins in type 1 diabetes. Front Immunol 2021; 11: 612584.
[http://dx.doi.org/10.3389/fimmu.2020.612584] [PMID: 33584694]
[36]
Huurman VAL, Decochez K, Mathieu C, Cohen IR, Roep BO. Therapy with the hsp60 peptide DiaPep277™ in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 2007; 23(4): 269-75.
[http://dx.doi.org/10.1002/dmrr.691] [PMID: 17024692]
[37]
Yu XZ, Levin SD, Madrenas J, Anasetti C. Lck is required for activation-induced T cell death after TCR ligation with partial agonists. J Immunol 2004; 172(3): 1437-43.
[http://dx.doi.org/10.4049/jimmunol.172.3.1437] [PMID: 14734719]
[38]
Ben-Amor A, Leite-De-Moraes MC, Lepault F, et al. In vitro T cell unresponsiveness following low-dose injection of anti-CD3 MoAb. Clin Exp Immunol 2007; 103(3): 491-8.
[http://dx.doi.org/10.1111/j.1365-2249.1996.tb08307.x] [PMID: 8608651]
[39]
Wallberg M, Recino A, Phillips J, et al. Anti-CD3 treatment up-regulates programmed cell death protein-1 expression on activated effector T cells and severely impairs their inflammatory capacity. Immunology 2017; 151(2): 248-60.
[http://dx.doi.org/10.1111/imm.12729] [PMID: 28211040]
[40]
Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 2005; 115(10): 2904-13. https://europepmc.org/articles/PMC1201661
[http://dx.doi.org/10.1172/JCI23961] [PMID: 16167085]
[41]
Li L, Ran T, Gao D, Ting Q, Yue DB. Was Mauritius really successful in banning plastic carry bags, after promulgation of the regulation prohibiting plastic bags usage? Environ Develop Sustainab 2021; 23(8): Available from:.
[http://dx.doi.org/10.1007/s10668-020-01134-w]
[42]
Small GW, McLeod HL, Richards KL. Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells. PeerJ 2013; 1: e31.
[http://dx.doi.org/10.7717/peerj.31] [PMID: 23638367]
[43]
Ivanova N, Gugleva V, Dobreva M, Pehlivanov I, Stefanov S, Andonova V. We are IntechOpen, the world’s leading publisher of Open Access books built by scientists, for scientists TOP 1%. Intech 2016; 2016: 13.
[44]
Ravetch JV, Lanier LL. Immune inhibitory receptors. Science 2000; 290(5489): 84-9.
[http://dx.doi.org/10.1126/science.290.5489.84] [PMID: 11021804]
[45]
Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22(47): 7359-68.
[http://dx.doi.org/10.1038/sj.onc.1206939] [PMID: 14576843]
[46]
Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6(4): 443-6.
[http://dx.doi.org/10.1038/74704] [PMID: 10742152]
[47]
Kalampokis I, Yoshizaki A, Tedder TF. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther 2013; (Suppl. 1)S1.
[48]
Alas S, Ng CP, Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin’s lymphoma. Clin Cancer Res 2002; 8(3): 836-45.
[PMID: 11895917]
[49]
Herold KC, Gitelman SE, Willi SM. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: A randomised controlled trial. Diabetologia 2013; 56(2): 391-400.
[http://dx.doi.org/10.1007/s00125-012-2753-4]

Rights & Permissions Print Cite
Article Metrics
72
3
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy